Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 17/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 16/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.73 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15936541 | 0.93 | HDAC3 (1.00) | HDAC3HDAC2HDAC1KCNH2NCOR2 | |
| SCHEMBL20181460 | 0.92 | HDAC2 (0.85) | HDAC3HDAC2HDAC1KCNH2NCOR2 | |
| SCHEMBL20181482 | 0.91 | HDAC2 (0.83) | HDAC3HDAC2HDAC1KCNH2NCOR2 | |
| SCHEMBL20181652 | 0.87 | HDAC2 (0.77) | HDAC3HDAC2HDAC1KCNH2NCOR2 | |
| SCHEMBL20181631 | 0.85 | HDAC2 (1.00) | HDAC3HDAC2HDAC1KCNH2 | |
| SCHEMBL15666003 | 0.84 | HDAC3 (1.00) | HDAC3HDAC2HDAC1KCNH2NCOR2 | |
| SCHEMBL20181471 | 0.84 | KCNH2 (1.00) | HDAC3HDAC2HDAC1KCNH2NCOR2 | |
| SCHEMBL29361448 | 0.84 | HDAC3 (1.00) | HDAC3HDAC2HDAC1KCNH2NCOR2 | |
| SCHEMBL15666356 | 0.84 | HDAC2 (1.00) | HDAC3HDAC2HDAC1KCNH2NCOR2 | |
| SCHEMBL15936542 | 0.80 | HDAC3 (1.00) | HDAC3HDAC2HDAC1KCNH2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200377465-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2020-12-03 | — | — | US | disclosed |
| US-10774056-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190330169-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2019-10-31 | — | — | US | disclosed |
| US-10385031-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385031-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | HDAC3 7/4885HDAC2 2/4885HDAC1 1/4885 |
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | HDAC3 8/4885HDAC2 2/4885HDAC1 1/4885 |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | HDAC3 6/4885HDAC2 2/4885HDAC1 1/4885 |
| US-10774056-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | HDAC3 7/4885HDAC2 2/4885HDAC1 1/4885 |
| US-20200377465-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | HDAC3 7/4885HDAC2 2/4885HDAC1 1/4885 |
| US-20190330169-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | HDAC3 6/4885HDAC2 2/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.